이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids

2026년 11월 19일 업데이트: Hua Li

Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial

This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.

The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.

The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.

Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.

연구 개요

상세 설명

Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.

Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.

Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.

연구 유형

중재적

등록 (추정된)

110

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100024
        • Beijing Chao Yang Hospital, Capital Medical University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

20년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
  • Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
  • Age 20 to 50 years and premenopausal, with or without future fertility plans.
  • No contraindications to laparoscopic surgery.

Exclusion Criteria:

  • Concomitant submucosal fibroids classified as FIGO types 0-2.
  • Findings suspicious for malignancy on preoperative assessment.
  • Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
  • Known severe hepatic or renal dysfunction.
  • Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
  • Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
  • Acute infection.
  • Inability to sign the informed consent form.
  • Known or suspected poor adherence that would prevent completion of the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Laparoscopic Ultrasound-Guided Myomectomy

Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal.

During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety.

활성 비교기: Conventional Laparoscopic Myomectomy

Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance.

Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Fibroid Removal Rate
기간: During surgery and within 3 months after surgery

For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100.

During surgery and within 3 months after surgery

2차 결과 측정

결과 측정
측정값 설명
기간
Operative Time
기간: During surgery

Duration of the surgical procedure, measured in minutes.

During surgery
Residual Uterine Fibroid Rate
기간: 3 months after surgery (+/- 14 days)

Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100.

3 months after surgery (+/- 14 days)
Difference Between Removed and Preoperatively Identified Fibroid Counts
기간: Preoperative assessment and during surgery

For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging.

Preoperative assessment and during surgery
Estimated Intraoperative Blood Loss
기간: During surgery

Estimated volume of blood lost during surgery, measured in milliliters.

During surgery
Participants With Intraoperative Complications
기간: During surgery

Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury.

During surgery
Participants With Postoperative Complications
기간: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)

Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits.

From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
Postoperative Length of Hospital Stay
기간: Perioperative

Time from completion of surgery to hospital discharge, measured in days.

Perioperative
Postoperative Pain Score
기간: 2 and 6 hours after surgery

Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain.

2 and 6 hours after surgery
Time to First Postoperative Ambulation
기간: Perioperative

Time from completion of surgery to first postoperative ambulation, measured in hours.

Perioperative
Time to First Postoperative Flatus
기간: Perioperative

Time from completion of surgery to first passage of flatus, measured in hours.

Perioperative
Duration of Postoperative Uterotonic Treatment
기간: Perioperative

Duration of postoperative uterotonic medication use, measured in hours.

Perioperative
Time to Postoperative Drain Removal
기간: Perioperative

Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed.

Perioperative
Participants With Postoperative Urinary Dysfunction
기간: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Participants With Postoperative Bowel Dysfunction
기간: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Change From Baseline in Female Sexual Function Index Score
기간: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.

Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Oswestry Disability Index Score
기간: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability.

Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Zung Self-Rating Anxiety Scale Score
기간: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety.

Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
15-Item Quality of Recovery Questionnaire Score
기간: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated.

Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2029년 1월 1일

연구 완료 (추정된)

2029년 12월 1일

연구 등록 날짜

최초 제출

2026년 10월 28일

QC 기준을 충족하는 최초 제출

2026년 11월 19일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 19일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

There is no plan to share de-identified individual participant data with researchers outside the study team.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다